Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2026, Vol. 58 ›› Issue (4): 686-691. doi: 10.19723/j.issn.1671-167X.2026.04.002

Previous Articles     Next Articles

Current status of prostate cancer screening research

Ming LIU*(), Huiling CHEN, Zhengtong LYU, Huimin HOU, Jiamin SUN   

  1. Department of Urology, Beijing Hospital, National Center for Gerontology, National Clinical Research Center for Gerontology, The Key Laboratory of Geriatrics of NHC, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100005, China
  • Received:2026-04-23 Online:2026-08-18 Published:2026-05-27
  • Contact: Ming LIU

RICH HTML

   

PDF (PC)

Abstract:

Prostate cancer is the second most common malignant tumor among men worldwide. Its early diagnosis relies on screening. How to increase the detection rate of clinically significant prostate cancer, avoid overdiagnosis and over-treatment of low-risk tumors, while also considering economic benefits, has become a core issue in the field of screening. Currently, international prostate cancer screening strategies are moving from a single prostate-specific antigen (PSA) screening to individualized risk stratification, and exploring the roles of various stratification tools, such as magnetic resonance imaging (MRI), new biomarkers, and risk prediction models. However, there is no universally recognized unified approach. In recent years, although the incidence of prostate cancer in China has increased rapidly, the early diagnosis rate is still low. This is directly related to the insufficient prevalence of prostate cancer screening in China. Moreover, China also faces problems such as the lack of a reasonable screening model for elderly high-risk populations, insufficient public awareness, and the absence of a refined screening path. Future work involves building stratified screening strategies suitable for the Chinese population based on Chinese data, promoting the transition of screening from opportunistic to systematic, and is a task that needs to be carried out.

Key words: Prostate tumor, Early cancer detection, Community health service, Multiparametric nuclear magnetic resonance

CLC Number: 

  • R737.25
1
Bray F , Laversanne M , Sung H , et al. Global cancer statistics 2022:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2024, 74 (3): 229- 263.
2
郑荣寿, 陈茹, 韩冰峰, 等. 2022年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2024, 46 (3): 221- 231.
3
Gan Y , Zhou H , Feng P , et al. Global trends and regional variations in PCa burden: A focus on China's rapid growth[J]. Urol Oncol Semin Orig Investig, 2025, 43 (9): 526.e17- 526.e31.
4
Zeng H , Zheng R , Sun K , et al. Cancer survival statistics in China 2019-2021:A multicenter, population-based study[J]. J Natl Cancer Cent, 2024, 4 (3): 203- 213.
5
李绪, 李荣欣, 关心, 等. 兰州地区目标人群前列腺癌筛查及异常PSA值影响因素分析[J]. 中国男科学杂志, 2022, 36 (3): 3- 13.
6
郑利伟, 宋灵敏, 王钢, 等. 基层医院基于医共体模式下前列腺癌筛查模式的初步探索[J]. 中华泌尿外科杂志, 2024, 45 (6): 416- 419.
7
Andriole GL , Crawford ED , Grubb RL Ⅲ , et al. Mortality results from a randomized prostate-cancer screening trial[J]. N Engl J Med, 2009, 360 (13): 1310- 1319.

doi: 10.1056/NEJMoa0810696
8
Hugosson J , Roobol MJ , Månsson M , et al. A 16-yr follow-up of the European randomized study of screening for prostate cancer[J]. Eur Urol, 2019, 76 (1): 43- 51.

doi: 10.1016/j.eururo.2019.02.009
9
Leenen RCA , Venderbos LDF , Helleman J , et al. Prostate cancer early detection in the European Union and UK[J]. Eur Urol, 2025, 87 (3): 326- 339.

doi: 10.1016/j.eururo.2024.07.019
10
Dushimova Z , Iztleuov Y , Chingayeva G , et al. Overdiagnosis and overtreatment in prostate cancer[J]. Diseases, 2025, 13 (6): 167.

doi: 10.3390/diseases13060167
11
Sharpley CF , Bitsika V , Christie DRH . "The worst thing was…": Prostate cancer patients' evaluations of their diagnosis and treatment experiences[J]. Am J Mens Health, 2018, 12 (5): 1503- 1509.

doi: 10.1177/1557988318772752
12
Nielsen SB , Spalletta O , Toft Kristensen MA , et al. Psychosocial consequences of potential overdiagnosis in prostate cancer a qualitative interview study[J]. Scand J Prim Health Care, 2020, 38 (4): 439- 446.

doi: 10.1080/02813432.2020.1843826
13
Millan B , Hoogenes J , Uy M , et al. Long-term impact of posterior reconstruction urethrovesical anastomosis during robot-assisted prostatectomy: A secondary analysis of a randomized cohort[J]. Can Urol Assoc J, 2025, 19 (8): 269- 274.
14
Gómez Rivas J , Gómez Dávila P , Tarrazo Antelo AM , et al. The future of prostate cancer screening in the European Union: PRAISE-U project[J]. Actas Urológicas Españolas Engl Ed, 2026, 50 (3): 501919.
15
Van Poppel H , Roobol MJ , Chandran A . Early detection of prostate cancer in the European Union: Combining forces with PRAISE-U[J]. Eur Urol, 2023, 84 (6): 519- 522.

doi: 10.1016/j.eururo.2023.08.002
16
Singh D , Carvalho AL , Mosquera I , et al. Monitoring of prostate cancer screening in the European Union: Development of key performance indicators through the PRAISE-U project[J]. eClinicalMedicine, 2025, 80, 103022.

doi: 10.1016/j.eclinm.2024.103022
17
Cornford P, Tilki D, van den Bergh RCN, et al. EAU guidelines on prostate cancer-uroweb[EB/OL]. (2026-04-02)[2026-04-03]. https://uroweb.org/guidelines/prostate-cancer.
18
Sweis J , Ofori B , Murphy AB . Concerns regarding prostate cancer screening guidelines in minority populations[J]. Prostate Cancer Prostatic Dis, 2024, 27 (4): 591- 593.

doi: 10.1038/s41391-023-00765-0
19
Möller F , Månsson M , Wallström J , et al. Prostate cancers in the prostate-specific antigen interval of 1.8-3 ng/ml: Results from the göteborg-2 prostate cancer screening trial[J]. Eur Urol, 2024, 86 (2): 95- 100.

doi: 10.1016/j.eururo.2024.01.017
20
Lophatananon A , Light A , Burns-Cox N , et al. Re-evaluating the diagnostic efficacy of PSA as a referral test to detect clinically significant prostate cancer in contemporary MRI-based image-guided biopsy pathways[J]. J Clin Urol, 2023, 16 (4): 264- 273.

doi: 10.1177/20514158211059057
21
Crocetto F , Musone M , Chianese S , et al. Blood and urine-based biomarkers in prostate cancer: Current advances, clinical applications, and future directions[J]. J Liq Biopsy, 2025, 9, 100305.

doi: 10.1016/j.jlb.2025.100305
22
Auvinen A , Tammela TLJ , Mirtti T , et al. Prostate cancer screening with PSA, kallikrein panel, and MRI: The ProScreen randomized trial[J]. JAMA, 2024, 331 (17): 1452.

doi: 10.1001/jama.2024.3841
23
McHugh JK , Bancroft EK , Saunders E , et al. Assessment of a polygenic risk score in screening for prostate cancer[J]. N Engl J Med, 2025, 392 (14): 1406- 1417.

doi: 10.1056/NEJMoa2407934
24
Robinson HS , Lee SS , Barocas DA , et al. Evaluation of blood and urine based biomarkers for detection of clinically-significant prostate cancer[J]. Prostate Cancer Prostatic Dis, 2025, 28 (1): 45- 55.

doi: 10.1038/s41391-024-00840-0
25
Kawada T , Shim SR , Quhal F , et al. Diagnostic accuracy of liquid biomarkers for clinically significant prostate cancer detection: A systematic review and diagnostic meta-analysis of multiple thresholds[J]. Eur Urol Oncol, 2024, 7 (4): 649- 662.

doi: 10.1016/j.euo.2023.10.029
26
Tosoian JJ , Sessine MS , Trock BJ , et al. MyProstateScore in men considering repeat biopsy: Validation of a simple testing approach[J]. Prostate Cancer Prostatic Dis, 2023, 26 (3): 563- 567.

doi: 10.1038/s41391-022-00633-3
27
Franco A , Autorino R . ExoDx test for prostate cancer: The future is liquid[J]. Prostate Cancer Prostatic Dis, 2023, 26 (3): 443- 444.

doi: 10.1038/s41391-023-00707-w
28
Vigneswaran HT , Eklund M , Discacciati A , et al. Stockholm3 in a multiethnic cohort for prostate cancer detection (SEPTA): A prospective multicentered trial[J]. J Clin Oncol, 2024, 42 (32): 3806- 3816.

doi: 10.1200/JCO.24.00152
29
McLeod OD , Palsdottir T , Walz J , et al. Cost analysis of prostate cancer care using a biomarker-enhanced diagnostic strategy with Stockholm3[J]. Eur Urol Open Sci, 2024, 66, 26- 32.

doi: 10.1016/j.euros.2024.05.010
30
Tilki D , Rejek N , Nohe F , et al. External validation of Stockholm3 in a retrospective German clinical cohort[J]. Eur Urol Focus, 2025, 11 (1): 82- 87.

doi: 10.1016/j.euf.2024.07.009
31
Ahmed HU , El-Shater Bosaily A , Brown LC , et al. Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS): A paired validating confirmatory study[J]. Lancet, 2017, 389 (10071): 815- 822.

doi: 10.1016/S0140-6736(16)32401-1
32
Bratt O , Godtman RA , Jiborn T , et al. Population-based organised prostate cancer testing: Results from the first invitation of 50-year-old men[J]. Eur Urol, 2024, 85 (3): 207- 214.

doi: 10.1016/j.eururo.2023.11.013
33
Messina E , Borrelli A , Sciarra A , et al. Primary noncontrast magnetic resonance imaging for prostate cancer screening: A randomized clinical trial (PROSA)[J]. Eur Urol, 2026, 89 (3): 246- 257.

doi: 10.1016/j.eururo.2025.11.024
34
Hugosson J , Carlsson S , Aus G , et al. Mortality results from the Göteborg randomised population-based prostate-cancer screening trial[J]. Lancet Oncol, 2010, 11 (8): 725- 732.

doi: 10.1016/S1470-2045(10)70146-7
35
Al-Monajjed R, Boschheidgen M, Lakes J, et al. Value of additional systematic cores during magnetic resonance imaging-guided targeted biopsy in prostate cancer screening for young men: Results from the PROBASE trial[J/OL]. Eur Urol Oncol, 2025. https://www.sciencedirect.com/science/article/pii/S2588931125002883?via%3Dihub. DOI: 10.1016/j.euo.2025.10.014.
36
陈惠铃, 吕政通, 侯惠民, 等. 社区体检前列腺癌筛查的效果和卫生经济学价值: 一项北京市东城区真实世界研究[J]. 中华泌尿外科杂志, 2025, 46 (12): 930- 936.
[1] Ling-yi XU,Miao HUI,Shu-hong ZHU,Zhao YANG,Meng-rui LI,Hong-yu YANG,Xi-zi ZHENG,Ji-cheng LV,Li YANG. Chronic kidney disease in community: Current state for screening and management [J]. Journal of Peking University (Health Sciences), 2022, 54(5): 1056-封三.
[2] PANG Ming-Fan, FENG Xing-Lin. Analysis on urban elderly people’s preference for prevention and treatment of non-communicable diseases [J]. Journal of Peking University(Health Sciences), 2014, 46(2): 220-225.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd